ondansetron has been researched along with Leucocythaemia in 9 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty-six children (ages 18 mo to 15 y) receiving intrathecal chemotherapy with either methotrexate or the combination of methotrexate, hydrocortisone, and Ara-C for the prophylactic treatment of central nervous system leukemia were randomly assigned to receive an infusion of normal saline or ondansetron at one of two doses (0." | 9.09 | Randomized, double-blind, crossover, placebo-controlled trial of intravenous ondansetron for the prevention of intrathecal chemotherapy-induced vomiting in children. ( Atlas, MP; Giugliano, DM; Mahan, RA; Parker, RI; Prakash, D, 2001) |
| "Inhibitory effects on acute nausea and emesis, safety and usefulness of a single oral dose of Ondansetron tablet were evaluated in 3 different dose levels for comparison by telephone registration system, in patients receiving non-platinum anti-cancer drugs." | 9.07 | [Examination of anti-emetic effect, safety and usefulness of single oral dose of ondansetron tablet in nausea and emesis induced by anti-cancer drugs--dose-finding study of ondansetron tablet in patients receiving non-platinum anti-cancer drugs]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Nukariya, N; Ohta, J; Ota, K; Taguchi, T; Tsukagoshi, S, 1992) |
| "We examined the anti-emetic effect, safety and usefulness of ondansetron hydrochloride, a selective 5-HT3 receptor antagonist, given orally once daily at the dosage of 4 mg, for 3 to 5 consecutive days to patients with nausea and emesis induced by non-platinum anti-cancer drugs such as cyclophosphamide, doxorubicin and carboplatin." | 9.07 | [Examination of inhibitory effect, safety and usefulness of SN-307 (ondansetron) administered orally once daily for 3-5 consecutive days on nausea and emesis associated with non-platinum anti-cancer drugs]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| " Initially, for his leukemia, he was treated with chemotherapy, which resulted in severe nausea and vomiting for which he was given ondansetron." | 7.74 | The successful use of ondansetron in a boy with both leukemia and Tourette syndrome. ( Gulisano, M; Marino, S; Rizzo, R; Robertson, MM, 2008) |
| " Physicians and pharmacists should be cautious for drug-drug interactions when pipamperon is prescribed, especially in combination with other QT-prolongating agents." | 5.48 | Drug-drug interaction related to the use of pipamperon and ondansetron in a child treated for leukemia. ( Bauters, T; Bordon, V; Buts, S; Laureys, G, 2018) |
| "Twenty-six children (ages 18 mo to 15 y) receiving intrathecal chemotherapy with either methotrexate or the combination of methotrexate, hydrocortisone, and Ara-C for the prophylactic treatment of central nervous system leukemia were randomly assigned to receive an infusion of normal saline or ondansetron at one of two doses (0." | 5.09 | Randomized, double-blind, crossover, placebo-controlled trial of intravenous ondansetron for the prevention of intrathecal chemotherapy-induced vomiting in children. ( Atlas, MP; Giugliano, DM; Mahan, RA; Parker, RI; Prakash, D, 2001) |
| "Inhibitory effects on acute nausea and emesis, safety and usefulness of a single oral dose of Ondansetron tablet were evaluated in 3 different dose levels for comparison by telephone registration system, in patients receiving non-platinum anti-cancer drugs." | 5.07 | [Examination of anti-emetic effect, safety and usefulness of single oral dose of ondansetron tablet in nausea and emesis induced by anti-cancer drugs--dose-finding study of ondansetron tablet in patients receiving non-platinum anti-cancer drugs]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Nukariya, N; Ohta, J; Ota, K; Taguchi, T; Tsukagoshi, S, 1992) |
| "Anti-emetic effects, safety and usefulness of Ondansetron given intravenously at 4 mg once daily for consecutive 3-5 days were investigated against nausea and emesis induced by non-platinum anticancer drugs." | 5.07 | [Examination of anti-emetic effect and safety of multiple intravenous doses of ondansetron in patients receiving nonplatinum anti-cancer drugs]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Nukariya, N; Ohta, J; Ota, K; Taguchi, T; Tsukagoshi, S, 1992) |
| "We examined the anti-emetic effect, safety and usefulness of ondansetron hydrochloride, a selective 5-HT3 receptor antagonist, given orally once daily at the dosage of 4 mg, for 3 to 5 consecutive days to patients with nausea and emesis induced by non-platinum anti-cancer drugs such as cyclophosphamide, doxorubicin and carboplatin." | 5.07 | [Examination of inhibitory effect, safety and usefulness of SN-307 (ondansetron) administered orally once daily for 3-5 consecutive days on nausea and emesis associated with non-platinum anti-cancer drugs]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| " Initially, for his leukemia, he was treated with chemotherapy, which resulted in severe nausea and vomiting for which he was given ondansetron." | 3.74 | The successful use of ondansetron in a boy with both leukemia and Tourette syndrome. ( Gulisano, M; Marino, S; Rizzo, R; Robertson, MM, 2008) |
| " Physicians and pharmacists should be cautious for drug-drug interactions when pipamperon is prescribed, especially in combination with other QT-prolongating agents." | 1.48 | Drug-drug interaction related to the use of pipamperon and ondansetron in a child treated for leukemia. ( Bauters, T; Bordon, V; Buts, S; Laureys, G, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (44.44) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bauters, T | 1 |
| Buts, S | 1 |
| Bordon, V | 1 |
| Laureys, G | 1 |
| Sun, Y | 1 |
| Liu, W | 1 |
| Wang, C | 1 |
| Meng, Q | 1 |
| Liu, Z | 1 |
| Huo, X | 1 |
| Yang, X | 1 |
| Sun, P | 1 |
| Sun, H | 1 |
| Ma, X | 1 |
| Peng, J | 1 |
| Liu, K | 1 |
| Rizzo, R | 1 |
| Marino, S | 1 |
| Gulisano, M | 1 |
| Robertson, MM | 1 |
| Gibbs, SJ | 1 |
| Cassoni, AM | 1 |
| Lacerda, JF | 1 |
| Martins, C | 1 |
| Carmo, JA | 1 |
| Lourenço, MF | 1 |
| Araújo Pereira, ME | 1 |
| Rodrigues, A | 1 |
| Juncal, C | 1 |
| Lacerda, JM | 1 |
| Parker, RI | 1 |
| Prakash, D | 1 |
| Mahan, RA | 1 |
| Giugliano, DM | 1 |
| Atlas, MP | 1 |
| Nukariya, N | 2 |
| Niitani, H | 3 |
| Taguchi, T | 3 |
| Furue, H | 3 |
| Ota, K | 3 |
| Tsukagoshi, S | 3 |
| Ariyoshi, Y | 3 |
| Ikeda, M | 3 |
| Akasaka, Y | 3 |
| Ohta, J | 3 |
| Suminaga, M | 1 |
6 trials available for ondansetron and Leucocythaemia
| Article | Year |
|---|---|
A pilot study to evaluate the cost-effectiveness of ondansetron and granisetron in fractionated total body irradiation.
Topics: Administration, Oral; Antiemetics; Bone Marrow Transplantation; Cost-Benefit Analysis; Drug Administ | 1996 |
Randomized trial of ondansetron, granisetron, and tropisetron in the prevention of acute nausea and vomiting.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Femal | 2000 |
Randomized, double-blind, crossover, placebo-controlled trial of intravenous ondansetron for the prevention of intrathecal chemotherapy-induced vomiting in children.
Topics: Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cr | 2001 |
[Examination of anti-emetic effect, safety and usefulness of single oral dose of ondansetron tablet in nausea and emesis induced by anti-cancer drugs--dose-finding study of ondansetron tablet in patients receiving non-platinum anti-cancer drugs].
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Brea | 1992 |
[Examination of anti-emetic effect and safety of multiple intravenous doses of ondansetron in patients receiving nonplatinum anti-cancer drugs].
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 1992 |
[Examination of inhibitory effect, safety and usefulness of SN-307 (ondansetron) administered orally once daily for 3-5 consecutive days on nausea and emesis associated with non-platinum anti-cancer drugs].
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 1992 |
3 other studies available for ondansetron and Leucocythaemia
| Article | Year |
|---|---|
Drug-drug interaction related to the use of pipamperon and ondansetron in a child treated for leukemia.
Topics: Butyrophenones; Child; Drug Interactions; Electrocardiography; Humans; Leukemia; Long QT Syndrome; M | 2018 |
Combination of dihydromyricetin and ondansetron strengthens antiproliferative efficiency of adriamycin in K562/ADR through downregulation of SORCIN: A new strategy of inhibiting P-glycoprotein.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfami | 2019 |
The successful use of ondansetron in a boy with both leukemia and Tourette syndrome.
Topics: Anti-Dyskinesia Agents; Antiemetics; Antineoplastic Agents; Biperiden; Brain; Child; Dose-Response R | 2008 |